Literature DB >> 30119257

Curcumin reduces Ly6Chi monocyte infiltration to protect against liver fibrosis by inhibiting Kupffer cells activation to reduce chemokines secretion.

Xiang-An Zhao1, Guangmei Chen2, Yong Liu3, Yuxin Chen3, Hongyan Wu4, Yali Xiong5, Guiyang Wang5, Bei Jia5, Yang Li5, Juan Xia5, Jian Wang5, Xiaomin Yan5, Zhaoping Zhang5, Rui Huang6, Chao Wu7.   

Abstract

Curcumin has been reported to have anti-fibrotic effect. However, the anti-fibrotic mechanism of curcumin for liver fibrosis remains obscure. In the presenting study, we aimed to investigate whether curcumin reduce chemokines secretion by inhibiting kupffer cells (KCs) activation to decrease Ly6Chi monocyte infiltration in the treatment of liver fibrosis. Liver fibrosis was induced by intraperitoneal carbon tetrachloride (CCl4)-injection in mice. Mice in curcumin group received curcumin treatment by gavage. Pretreatment with curcumin significantly protected mice from liver inflammation and fibrosis. Compared to CCl4 group, mice in the curcumin group showed significantly less intrahepatic infiltration of Ly6Chi monocytes, but no difference of other leucocyte subtypes. Moreover, curcumin significantly reduced Ly6Chi monocytes associated pro-inflammatory and pro-fibrogenic cytokines, which was in line with the decreased numbers of intrahepatic Ly6Chi monocytes. Further study found that curcumin is able to decrease KCs activation and monocyte chemokines, which explains why curcumin can reduce Ly6Chi monocytes infiltration during liver fibrosis. In vitro, we discovered that curcumin prevents the polarization of macrophages toward M1 and reduces monocyte chemokines secretion, which is involved with ERK1/2 and p38 pathways. Taken together, for the first time, we verified that curcumin can reduce chemokines secretion by inhibiting KCs activation to decrease Ly6Chi monocyte infiltration in the treatment of liver fibrosis. These results suggested that curcumin may be considered a promising candidate in the prevention and treatment of liver fibrosis.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Chemokines; Curcumin; KCs; Liver fibrosis; Ly6C(hi) monocytes

Mesh:

Substances:

Year:  2018        PMID: 30119257     DOI: 10.1016/j.biopha.2018.07.028

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  7 in total

1.  HOXB13 expression is correlated with hepatic inflammatory activity of patients with hepatic fibrosis.

Authors:  Lingyun Zuo; Tingting Tan; Cheng Wei; Huali Wang; Luxuan Tan; Yingying Hao; Jingjing Qian; Yuxin Chen; Chao Wu
Journal:  J Mol Histol       Date:  2020-03-21       Impact factor: 2.611

2.  Intrahepatic Expression of C-C Motif ligand 5 in Patients with Chronic Hepatitis B.

Authors:  Xiang-An Zhao; Jian Wang; Haiyan Chang; Yong Liu; Yuxin Chen; Guangmei Chen; Rui Huang; Chao Wu
Journal:  Turk J Gastroenterol       Date:  2021-01       Impact factor: 1.852

3.  Margatoxin mitigates CCl4‑induced hepatic fibrosis in mice via macrophage polarization, cytokine secretion and STAT signaling.

Authors:  Bao-Ming Wu; Jun-Da Liu; Yuan-Hai Li; Jun Li
Journal:  Int J Mol Med       Date:  2019-11-04       Impact factor: 4.101

4.  Therapeutic potential of a novel combination of Curcumin with Sulfamethoxazole against carbon tetrachloride-induced acute liver injury in Swiss albino mice.

Authors:  Rasha Fekry Zahran; Zeinab M Geba; Ashraf A Tabll; Mohammad M Mashaly
Journal:  J Genet Eng Biotechnol       Date:  2020-05-04

Review 5.  Molecular Mechanisms and Potential New Therapeutic Drugs for Liver Fibrosis.

Authors:  Fa-Da Wang; Jing Zhou; En-Qiang Chen
Journal:  Front Pharmacol       Date:  2022-02-11       Impact factor: 5.810

6.  Network Pharmacological Analysis and Experimental Validation of the Mechanisms of Action of Si-Ni-San Against Liver Fibrosis.

Authors:  Siliang Wang; Cheng Tang; Heng Zhao; Peiliang Shen; Chao Lin; Yun Zhu; Dan Han
Journal:  Front Pharmacol       Date:  2021-07-01       Impact factor: 5.810

Review 7.  G Protein-Coupled Receptor Kinase 2 as Novel Therapeutic Target in Fibrotic Diseases.

Authors:  Nan Li; Shan Shan; Xiu-Qin Li; Ting-Ting Chen; Meng Qi; Sheng-Nan Zhang; Zi-Ying Wang; Ling-Ling Zhang; Wei Wei; Wu-Yi Sun
Journal:  Front Immunol       Date:  2022-01-17       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.